Femasys Inc. Common Stock (FEMY)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor first, so I ask whether this business has durable earnings power and a margin of safety. Femasys sells women's reproductive health devices, including FemaSeed and FemVue, but the financials show a very early, cash-consuming enterprise. In fiscal FY2025 (period ended 2025-12-31), revenue was $2.3M and net loss was $18.6M, or diluted EPS -$0.47. In fiscal FY2024 (period ended 2024-12-31), revenue was $1.6M and net loss was $18.8M. In fiscal FY2023 (period ended 2023-12-31), net loss was $14.2M. The latest filed quarter, fiscal Q2 2026 (quarter ended 2026-06-30), had revenue of $331,827, net loss of $4.5M, and diluted EPS of -$1.33. That revenue was below the $409,268 reported in fiscal Q2 2025 (quarter ended 2025-06-30). Free cash flow is deeply negative: -$18.2M trailing twelve months, a -123.4% FCF yield on a $14.7M market cap, per FairStock. Piotroski is 2/9 and Altman Z-Score is -16.85, both FairStock calculations, signaling weak financial strength and distress risk. Debt/equity is 1.19. At the $1.76 close on 2026-10-13, FairStock P/B is 1.32 and P/E is -0.65. A low P/B can look cheap, but book value is being eroded by losses, and there is no demonstrated moat. The computed Lynch category is none because it lost money in each of the last four years. I see speculative optionality, not a Graham-style bargain.

In plain English: Femasys makes medical devices for women's reproductive health. The business is very small and still losing money: sales are tiny, losses are large, and it uses more cash than it brings in. At $1.76, the stock may look cheap next to its book value, but the weak finances and lack of profits make it hard to call a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer